Further available immunization option to prevent pneumococcal disease

In their recent review, Charles Feldman and Ronald Anderson provide an overview of various clinical aspects of pneumococcal infections. We would like to complete this report by providing some additional information on a widely-used immunization option, which was not originally mentioned in the artic...

Descripción completa

Detalles Bibliográficos
Autores principales: Vojtek, Ivo, Hoet, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2015
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376167/
https://www.ncbi.nlm.nih.gov/pubmed/25866621
http://dx.doi.org/10.12688/f1000research.5990.1
_version_ 1782363695814279168
author Vojtek, Ivo
Hoet, Bernard
author_facet Vojtek, Ivo
Hoet, Bernard
author_sort Vojtek, Ivo
collection PubMed
description In their recent review, Charles Feldman and Ronald Anderson provide an overview of various clinical aspects of pneumococcal infections. We would like to complete this report by providing some additional information on a widely-used immunization option, which was not originally mentioned in the article. The protein D pneumococcal conjugate vaccine (PHiD-CV) has been pre-approved by WHO and its impact is supported by real-life data from the regions of its use.
format Online
Article
Text
id pubmed-4376167
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-43761672015-04-09 Further available immunization option to prevent pneumococcal disease Vojtek, Ivo Hoet, Bernard F1000Res Correspondence In their recent review, Charles Feldman and Ronald Anderson provide an overview of various clinical aspects of pneumococcal infections. We would like to complete this report by providing some additional information on a widely-used immunization option, which was not originally mentioned in the article. The protein D pneumococcal conjugate vaccine (PHiD-CV) has been pre-approved by WHO and its impact is supported by real-life data from the regions of its use. F1000Research 2015-01-07 /pmc/articles/PMC4376167/ /pubmed/25866621 http://dx.doi.org/10.12688/f1000research.5990.1 Text en Copyright: © 2015 Vojtek I and Hoet B http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/publicdomain/zero/1.0/ Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).
spellingShingle Correspondence
Vojtek, Ivo
Hoet, Bernard
Further available immunization option to prevent pneumococcal disease
title Further available immunization option to prevent pneumococcal disease
title_full Further available immunization option to prevent pneumococcal disease
title_fullStr Further available immunization option to prevent pneumococcal disease
title_full_unstemmed Further available immunization option to prevent pneumococcal disease
title_short Further available immunization option to prevent pneumococcal disease
title_sort further available immunization option to prevent pneumococcal disease
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376167/
https://www.ncbi.nlm.nih.gov/pubmed/25866621
http://dx.doi.org/10.12688/f1000research.5990.1
work_keys_str_mv AT vojtekivo furtheravailableimmunizationoptiontopreventpneumococcaldisease
AT hoetbernard furtheravailableimmunizationoptiontopreventpneumococcaldisease

Ejemplares similares